Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment, has released a Virtual Investor "What This Means" segment. In this presentation, Chief Medical Officer Dr. Robert Schwartz discusses the company's recent post hoc analysis of their proof-of-concept human clinical trial (PoC 1).
The analysis revealed significant outcomes including sustained pain reduction, improved quality of life, and 100% zero opioid use among trial participants. The company's focus remains on advancing innovative technologies in neurological disease management.
Positive
- Post hoc analysis showed sustained pain reduction in clinical trial participants
- Trial demonstrated 100% zero opioid use among participants
- Results showed quality of life improvements for patients
Negative
- None.
News Market Reaction
On the day this news was published, AMIX declined 8.90%, reflecting a notable negative market reaction. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $651K from the company's valuation, bringing the market cap to $7M at that time.
Data tracked by StockTitan Argus on the day of publication.
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced results from the post hoc analysis of its proof-of-concept human clinical trial (“PoC 1”)
THE WOODLANDS, TX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the release of a Virtual Investor “What This Means” segment.
For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company’s recently announced longer-term post hoc analysis results from its proof-of-concept human clinical trial (“PoC 1”) which demonstrated sustained pain reduction, quality of life gains and
The “What This Means” segment can be accessed here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What were the key findings from Autonomix Medical's (NASDAQ: AMIX) PoC 1 clinical trial analysis?
Who presented Autonomix Medical's clinical trial results in the Virtual Investor segment?
What is Autonomix Medical's (AMIX) main business focus?
Where can investors access Autonomix Medical's Virtual Investor segment presentation?
